前列腺癌和前列腺癌床与ProstaScint SPECT成像:半定量的相关性与前列腺活检的结果。

文章的细节

引用

复制到剪贴板

Sodee DB,埃利斯RJ塞缪尔,斯皮纳克JP,普尔WF,里斯C, Martanovic DM,是不是应该R, Bellon EM

前列腺癌和前列腺癌床与ProstaScint SPECT成像:半定量的相关性与前列腺活检的结果。

前列腺癌。1998年11月1日,37 (3):140 - 8。

PubMed ID

9792131 (在PubMed

]

文摘

背景:ProstaScint (Cytogen公司,普林斯顿,纽约)小鼠单克隆抗体成像是fda批准的成像高危前列腺癌患者的转移性疾病和患者postprostatectomy与崛起的血清前列腺特异性抗原(PSA)水平。ProstaScint小鼠单克隆抗体,目标前列腺特异性膜抗原(PSMA)。表达式是调节PSMA原发性和转移性前列腺癌。FDA Cytogen(普林斯顿,纽约)协议研究使用111 indium-labeled ProstaScint显示领域增加浓度之间的相关性在前列腺癌和biopsy-proven成像pretherapy肿瘤病人。方法:在我们的研究中,四横,单光子发射断层扫描(SPECT)图像被孤立和地区感兴趣的选择和与pretherapy前列腺活检的结果。前列腺癌和前列腺正常组织/肌肉背景(P / M)比率是派生的,所以,postprostatectomy /放疗患者可以评估残留前列腺癌的存在。23 pretherapy前列腺癌患者象限/六分仪活检SPECT 96 - hr 111铟ProstaScint盆腔图像。上面的四个横向1厘米的片中线阴茎血池的选择,和四到六27-30-pixel地区感兴趣的在前列腺的床被。背景肌肉地区的利益放在外部闭孔肌肉。P / M值计算,而象限/六分仪前列腺活检的结果。 The same procedure was applied to 17 posttherapy prostate cancer patients with rising PSA. RESULTS: In the 23 pretherapy prostate cancer patients, there was a correlation between the P/M ratio of at least 3.0 in 32 of 35 prostatic cancer biopsy regions, and there was correlation with P/M ratios less than 3.0 in 82 of 89 negative biopsy regions. Seventeen posttherapy patients underwent ProstaScint studies. Six underwent biopsy, with typically one biopsy site per patient. All 6 had P/M ratios greater than 3.0 in the biopsied region. Five out of six biopsies revealed residual prostate cancer. CONCLUSIONS: A prostate/muscle ratio was developed from 111indium ProstaScint regions of interest obtained on 1-cm SPECT transverse slices through the prostate bed in 23 patients preprostatic cancer therapy. A P/M ratio above 3.0 correlated in the majority of positive cases, and a P/M ratio below 3.0 was demonstrated in negative prostatic biopsy cases. The P/M ratio of above 3.0 or below 3.0 also separated those posttherapy prostate cancer patients with rising PSA who had residual prostate carcinoma in the prostate bed.

DrugBank数据引用了这篇文章

药物靶点

药物	目标	类	生物	药理作用	行动
Capromab pendetide	谷氨酸羧肽酶2	蛋白质	人类	是的	其他/未知	细节